As of Wednesday, February 18, Cartesian Therapeutics, Inc.’s RNAC share price has dipped by 8.15%, which has investors questioning if this is right time to buy.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in ...

Special edition of Globe Magazine honors the best employers in Massachusetts BOSTON, MA, UNITED STATES, January 14, 2026 /EINPresswire.com/ — Cartesian has been ...

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...